We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biohaven Pharmaceutical (BHVN - Free Report) incurred a loss of $3.01 per share in fourth-quarter 2021, wider than the Zacks Consensus Estimate of a loss of $2.07 but narrower than the year-ago loss of $3.62.
Adjusted loss, which excludes non-cash stock-based compensation and a few other non-cash expenses, for the fourth quarter was $2.32 per share compared with $2.69 in the year-ago period.
Total revenues, solely from Nurtec ODT, were $190 million in the fourth quarter, in line with the Zacks Consensus Estimate. Sales were up 40% sequentially and 441% year over year on the back of strong demand and higher net price realization. Please note that the company had launched Nurtec ODT in March 2020.
Shares of Biohaven declined 8.9% on Feb 25, following the wider-than-expected loss in the fourth quarter. However, the company's shares have gained 41.2% in the past year against the industry’s decrease of 37.6%.
Image Source: Zacks Investment Research
Quarter in Detail
Research and development (R&D) expenses, including stock-based compensation, were $91.1 million in the quarter, up 23.9% year over year, driven by higher pre-clinical and late-stage clinical activities.
Selling, general and administrative (SG&A) expenses were $219.5 million in the quarter, up 79.3% from the year-ago period. The significant increase in SG&A expense was driven by higher costs to support the commercialization of Nurtec.
As of Dec 31, 2021, Biohaven had cash and restricted cash worth $367 million compared with $523.9 million as of Sep 30, 2021.
Full-Year Results
Biohaven reported revenues of $462.5 million for 2021, compared with $63.6 million in revenues in 2020. In 2021, the company incurred a loss of $13.09 per share, widening from $13.06 per share from the year-ago period. Adjuted loss in 2021 was $9.86 per share, narrowing 4.4% year over year.
Nurtec Update
In a separate press release, Biohaven stated that its oral anti-CGRP drug, Nurtec ODT, was recommended by the Committee for Medicinal Products for Human Use for approval in Europe as an acute and preventive treatment for migraine. The company expects approval from the European Commission in the first half of 2022. During the fourth quarter, the drug received approval in Israel as acute and preventive treatment and in Kuwait as an acute treatment for migraine.
In November 2021, Biohaven inked a strategic agreement with Pfizer (PFE - Free Report) for the commercialization of Nurtec ODT in ex-U.S. markets. The deal with Pfizer was completed last month. Biohaven recorded an upfront payment of $500 million upon completion which included $150 million in cash and the rest in equity investment. Biohaven is eligible to receive up to $740.0 million in future milestones from Pfizer along with royalties on net sales of Nurtec ODT outside the United States. Per the same deal, Pfizer also gained rights to another candidate in Biohaven’s pipeline, zavegepant, which is also being developed as a migraine treatment.
Earlier this month, Biohaven announced top-line data from a phase III study evaluating Nurtec ODT in migraine patients in China and South Korea. Data from the study was consistent with previous studies, which supported the drug’s approval in the United States. Data from this study will support the regulatory application, expected to be filed in the second half of 2022, for the potential approval of the drug in China and South Korea.
In February, Biohaven initiated a phase II/III study to evaluate Nurtec ODT as a potential treatment for chronic rhinosinusitis. The company is planning a clinical study in the first quarter of 2022 to evaluate Nurtec ODT as a potential treatment for temporomandibular disorder.
License Agreements
Earlier this month, Biohaven expanded its pipeline through two new agreements with Bristol-Myers (BMY - Free Report) and privately-held Knopp Biosciences.
Biohaven signed a worldwide license agreement, with Bristol-Myers gaining development and commercialization rights to the latter’s phase III-ready pipeline candidate, taldefgrobep alfa. Biohaven is planning to start a phase III study to evaluate the candidate in patients with spinal muscular atrophy later this year. Biohaven will pay Bristol-Myers regulatory approval milestone payments and sales-based royalties related to taldefgrobep alfa development and commercialization.
Biohaven added an epilepsy candidate, BHV-7000, under its agreement with Knopp Biosciences to acquire the latter’s Kv7 channel targeting platform. The company plans to start a clinical study on the candidate later this year. Per the same agreement, Biohaven also gains rights to other pipeline candidates from Knopp Biosciences’s Kv7 channel targeting platform.
Biohaven Pharmaceutical Holding Company Ltd. Price, Consensus and EPS Surprise
Image: Bigstock
Biohaven's (BHVN) Q4 Earnings Miss, Nurtec Gets CHMP Nod
Biohaven Pharmaceutical (BHVN - Free Report) incurred a loss of $3.01 per share in fourth-quarter 2021, wider than the Zacks Consensus Estimate of a loss of $2.07 but narrower than the year-ago loss of $3.62.
Adjusted loss, which excludes non-cash stock-based compensation and a few other non-cash expenses, for the fourth quarter was $2.32 per share compared with $2.69 in the year-ago period.
Total revenues, solely from Nurtec ODT, were $190 million in the fourth quarter, in line with the Zacks Consensus Estimate. Sales were up 40% sequentially and 441% year over year on the back of strong demand and higher net price realization. Please note that the company had launched Nurtec ODT in March 2020.
Shares of Biohaven declined 8.9% on Feb 25, following the wider-than-expected loss in the fourth quarter. However, the company's shares have gained 41.2% in the past year against the industry’s decrease of 37.6%.
Image Source: Zacks Investment Research
Quarter in Detail
Research and development (R&D) expenses, including stock-based compensation, were $91.1 million in the quarter, up 23.9% year over year, driven by higher pre-clinical and late-stage clinical activities.
Selling, general and administrative (SG&A) expenses were $219.5 million in the quarter, up 79.3% from the year-ago period. The significant increase in SG&A expense was driven by higher costs to support the commercialization of Nurtec.
As of Dec 31, 2021, Biohaven had cash and restricted cash worth $367 million compared with $523.9 million as of Sep 30, 2021.
Full-Year Results
Biohaven reported revenues of $462.5 million for 2021, compared with $63.6 million in revenues in 2020. In 2021, the company incurred a loss of $13.09 per share, widening from $13.06 per share from the year-ago period. Adjuted loss in 2021 was $9.86 per share, narrowing 4.4% year over year.
Nurtec Update
In a separate press release, Biohaven stated that its oral anti-CGRP drug, Nurtec ODT, was recommended by the Committee for Medicinal Products for Human Use for approval in Europe as an acute and preventive treatment for migraine. The company expects approval from the European Commission in the first half of 2022. During the fourth quarter, the drug received approval in Israel as acute and preventive treatment and in Kuwait as an acute treatment for migraine.
In November 2021, Biohaven inked a strategic agreement with Pfizer (PFE - Free Report) for the commercialization of Nurtec ODT in ex-U.S. markets. The deal with Pfizer was completed last month. Biohaven recorded an upfront payment of $500 million upon completion which included $150 million in cash and the rest in equity investment. Biohaven is eligible to receive up to $740.0 million in future milestones from Pfizer along with royalties on net sales of Nurtec ODT outside the United States. Per the same deal, Pfizer also gained rights to another candidate in Biohaven’s pipeline, zavegepant, which is also being developed as a migraine treatment.
Earlier this month, Biohaven announced top-line data from a phase III study evaluating Nurtec ODT in migraine patients in China and South Korea. Data from the study was consistent with previous studies, which supported the drug’s approval in the United States. Data from this study will support the regulatory application, expected to be filed in the second half of 2022, for the potential approval of the drug in China and South Korea.
In February, Biohaven initiated a phase II/III study to evaluate Nurtec ODT as a potential treatment for chronic rhinosinusitis. The company is planning a clinical study in the first quarter of 2022 to evaluate Nurtec ODT as a potential treatment for temporomandibular disorder.
License Agreements
Earlier this month, Biohaven expanded its pipeline through two new agreements with Bristol-Myers (BMY - Free Report) and privately-held Knopp Biosciences.
Biohaven signed a worldwide license agreement, with Bristol-Myers gaining development and commercialization rights to the latter’s phase III-ready pipeline candidate, taldefgrobep alfa. Biohaven is planning to start a phase III study to evaluate the candidate in patients with spinal muscular atrophy later this year. Biohaven will pay Bristol-Myers regulatory approval milestone payments and sales-based royalties related to taldefgrobep alfa development and commercialization.
Biohaven added an epilepsy candidate, BHV-7000, under its agreement with Knopp Biosciences to acquire the latter’s Kv7 channel targeting platform. The company plans to start a clinical study on the candidate later this year. Per the same agreement, Biohaven also gains rights to other pipeline candidates from Knopp Biosciences’s Kv7 channel targeting platform.
Biohaven Pharmaceutical Holding Company Ltd. Price, Consensus and EPS Surprise
Biohaven Pharmaceutical Holding Company Ltd. price-consensus-eps-surprise-chart | Biohaven Pharmaceutical Holding Company Ltd. Quote
Zacks Rank
Biohaven currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A better-ranked drugmaker is Collegium Pharmaceutical (COLL - Free Report) , sporting a Zacks Rank of 1.
Collegium’s earnings per share estimates have moved north from $3.66 to $5.43 for 2022 in the past 30 days. COLL has gained 3.6% so far this year.
Collegium delivered a negative earnings surprise of 22.76%, on average, in the last four quarters.